HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
NCT05360368
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
HLX07
Sponsor
Shanghai Henlius Biotech